A Deep Dive Into CVOTs

Complications of Diabetes

SAVOR, EXAMINE, and TECOS Key Results

EMPA-REG OUTCOME Cardiovascular Outcomes and Death From Any Cause

EMPA-REG OUTCOME HbA1c Levels and Blood Pressure

EMPA-REG OUTCOME Renal Outcomes

ELIXA Lixisenatide CVOT

LEADER Liraglutide CVOT

Lixisenatide and Liraglutide

Empagliflozin and Liraglutide

Individual Components of the Primary Endpoint

Drug Safety GLP-1 Receptor Agonists and SGLT2 Inhibitors

SGLT2 Inhibitors and GLP-1 Receptor Agonists: FDA Warnings and Precautions

Clinical Application of These CVOT Data

Are There Patient Populations That Favor Use of One Class Over Another?

FIGHT Study

Ongoing SGLT2 and DPP-4 Inhibitor CVOTs

Ongoing GLP-1 Receptor Agonist CVOTs

Closing Comments

Abbreviations